Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...
Healio

Nerandomilast reduces FVC decline in US patients with IPF

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...
The American Journal of Managed Care

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic ...
The American Journal of Managed Care

Nerandomilast Slows Lung Function Decline in Patients With IPF

Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients, 78% ...
Medscape

Less FVC Decline in Progressive PF With Oral Nerandomilast

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
News Medical

Menopausal women may experience accelerated decline in lung function, research shows

Menopausal women appear to experience an accelerated decline in lung function, according to new research published online ahead of print in the American Thoracic Society's American Journal of ...